Tricyclic antidepressant (norepinephrine reuptake inhibitor)

  • Major Depression
  • Treatment resistant depression
  • Low sedation
  • ADHD

Dosing

75-300 mg/d, start 25-50 mg/d.

Serum level is options (target 150-300)

Management

Strongest norepinephrine effects. Lowest anticholinergic burden. Low risk of sedation.

TOLERABILITY: ANTICHOLINERGIC: Constipation (treat docusate 100 mg BID + sennosides 8.6 mg; bethanechol 10-25 mg tid if severe), urinary retention (treat bethanechol 25mg tid), dry mouth (treat spry gum tid, biotene; or pilocarpine swish), blurry vision, confusion.

RISKS: HEART: Orthostatic hypotension (treat elastic abdominal binders or support stockings; if severe, fludrocortisone 0.1-0.2 mg qd or midrodine 0.5 mg tid), falls, cardiac arrhythmias; HEPATOTOXICITY: Extremely rare (4 per 100,000 patient-years).

EMR Text

Depression

Desipramine use based on FDA approval in major depressive disorder.

Desipramine side effects, including cardiac, hypotension, and hepatotoxicity, reviewed with patient.

Scroll to Top